Retinal disease management has witnessed remarkable advances in posterior segment pharmacotherapy with the development of anti-VEGF molecules such as Lucentis ®
Introduction
After the original anti-VEGF disruptor therapeutic agent, bevacizumab (Avastin, Genentech, South San Francisco, CA, USA), used with dramatic success in the management of various retinal diseases including wet age-related macular degeneration (AMD), macular edema due to retinal vein occlusion (RVO), and diabetic macular edema (DME), ophthalmology is poised for another disruptor in the form of biosimilar molecules predominantly to be used in the management of posterior segment diseases. This review will provide an understanding of biosimilar molecules, potential candidates on horizon and some which are already showing promise, and the likely impact of their entry in the developing and developed world.
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Sharma et al which could differ from the originator molecules; hence, the structure is not predefined as compared to generic drugs. Furthermore, most of the generic drugs are stable because they are generated through fixed chemical formula and synthesis. However, biosimilars need extra caution in terms of stability. Immunogenicity can be an issue with biosimilars due to different living cells and process followed by different biosimilar developers, which is not the case with generics. In a nutshell, biosimilar need not be the exact copy in terms of formulation, but it should show similar efficacy, safety, and quality.
How difficult is to manufacture a biosimilar?
Biosimilars are large molecules compared to generics and, as mentioned previously, they are not based on a fixed chemical formula; so, it is not easy to manufacture biosimilars. The major reason is that originator biologics do not provide complete information in terms of the process followed during the manufacturing even after expiry of their patent. Biosimilar drug makers get partial information, and most of the time they need to get cues from the original biologic drugs available in the market via reverse engineering. Furthermore, biosimilar manufacturing involves a big investment upfront compared to generic drug development. Most of the companies which are in the race for developing biosimilars are aware of this and have refined their manufacturing process to capture the next wave of a multibillion USD market. On the flip side, there is a possibility of biosimilar drugs being better (biobetter) than reference biologic because biosimilar companies use the latest technology compared to the technology used by reference biologics.
why is there a race to develop biosimilars?
As mentioned above, it is not easy to manufacture these molecules; then why there is a race among multiple drug makers globally to bring these molecules in the market as soon as possible. The reason behind is the cost involved vs profit. The cost and time to develop a biosimilar are much less than original biologics. Typically, biologics will take 10-15 years to develop with an expenditure of USD 1,200-2,500 million. However, biosimilars can be manufactured in 8-10 years with approximately 1/10th of the cost (USD 100-200 million). [1] [2] [3] The reason behind cost and time-saving in cases of biosimilars is that biosimilars need not invest heavily on clinical trials, rather they need to have robust analytical bioequivalence to prove similarity. At least one clinical study is required to compare pharmacokinetics of bio-originator and biosimilar, and at least one sufficiently large randomized controlled trial to demonstrate clinical equivalence.
In the year 2016, Lucentis ® (ranibizumab, Genentech, South San Francisco, CA) clocked sales of $1.4 billion for Roche (Basel, Switzerland) Diabetic retinopathy market size was valued at around USD 7 billion in 2016 and is anticipated to witness a growth of over 6.5% mean annual growth rate (CAGR) from 2017 to 2024. 5 The wet AMD market is expected to be USD 8 billion+ by 2020. The global age-related macular degeneration (AMD) market size is predicted to reach $8.9 billion by 2022, growing at a CAGR of 7.6% during the forecast period.
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This time and cost factor in manufacturing biosimilars along with multibillion dollar market with growth are prompting major drug companies to get into the biosimilar market, which can give them big gains in terms of profitability.
Biosimilar approval process is it the same globally?
No it is not. Europe is the most experienced region regarding having a developed regulatory framework for biosimilars. [7] [8] [9] There are no fixed guidelines globally regarding their approval. Guidelines are constantly evolving as technology grows. However, fundamentals of the guidelines across the world are the following: 1. Analytical studies to demonstrate high biosimilarity. 2. Animal studies for toxicity assessment. 3. The clinical study to assess safety, efficacy, and immunogenicity compared to the reference biologic. There are multiple steps to assess above three described points. Each country has a committee which decides the next step of evidence on the basis of the strength of similarity in the previous step.
Does a biosimilar need to go through separate approval for each indication?
No, it can be approved for all the indications for which the reference biologic is being used provided analytical, 
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Potential biosimilars on the horizon Biosimilar to ranibizumab
Razumab ® (Intas Pharmaceuticals Ltd., Ahmedabad, India) -Razumab became the first and the only similar biologic to ranibizumab being clinically used at this point in time. It was approved by the regulatory body from India in 2015 based on the results of Phase 3 Clinical trial in 104 Indian patients with wet AMD (Table 1 ). In addition to registration clinical trial, Intas also conducted RE-ENACT study (a retrospective pooled analysis) to assess the real-world experience of razumab in 561 Indian patients with wet AMD, RVO, and DME. The subgroup analyses data from the RE-ENACT study for wet AMD (n=194) and RVO (n=160) populations have been published recently. 10, 11 It is a recombinant humanized IgG1 monoclonal antibody fragment designed for intraocular use. It comes in a single-use glass vial like the reference product with a concentration of 10 mg/mL in 0.05 mL. Ocular inflammation was reported with the initial three batches of the drug. However, the company took immediate action and resolved the issues by halting production for some time, and after refining the manufacturing process slowly started releasing the batches with careful monitoring. The drug has proved its safety and efficacy since then, and data have been presented at various scientific platforms such as American Society of Retina Specialists, Euretina, and American Academy of Ophthalmology regarding the same. Razumab is approved for all the indications in which ranibizumab is used (wet AMD, DME, RVO, and myopic choroidal neovascularization). [12] [13] [14] Current status -Razumab is doing well in the Indian market and expanding its user base. Study demonstrated similarity to the reference product on most of the tested parameters. However, purity was found to be lower compared to the reference product. The company will be doing some modifications in the manufacturing process to match the purity when they scale up the production process. Current status -Xbranes is open for global partners to go further in terms of approval and commercialization. There is the possibility of Xbrane and CR Pharma (Hong Kong, People's Republic of China) 
Biosimilar to Avastin ® (bevacizumab)
There are biosimilars to Avastin already approved and in the pipeline. However, their use is more suited in oncology rather than ophthalmology due to the cost-effective availability of bevacizumab globally along with the faith of ophthalmologists in it. Bevacizumab biosimilars approved for clinical use in different countries are briefly mentioned in Table 3 .
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Biosimilar to Humira ® (adalimumab)
Bevacizumab, ranibizumab, and aflibercept have been the extensively used drugs in ophthalmology. However, there is a small segment of patients with noninfectious uveitis who might benefit with a cost-effective biosimilar to adalimumab (Humira). Table 4 lists the approved biosimilars of adalimumab.
Is there a big change around the corner?
There is a strong possibility of a shift toward biosimilar in both developing and developed world for different reasons. 
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Developed world
The major reason is that insurance companies will have significant savings of 15%-20% due to recurrent injections. Furthermore, it can save government expenditure on health. In the United States, biosimilars are estimated to save $44 billion from 2014 to 2024. 25 Insurance and cost-saving strategies by the government might uplift the biosimilar use rather than the real clinician-based upsurge in short term. Clinicians have developed confidence over a long time use in off-label bevacizumab which is cost-effective (USD 50) over ranibizumab and aflibercept. Clinicians will take time to gain faith in new cost-effective drugs (biosimilars) when they have a cheaper drug already available.
Developing world
The equation can significantly change in developing countries where bevacizumab compounding has been an issue and bevacizumab has faced temporary ban due to regulatory agencies such as in India. 26 Biosimilars have potential to fill that gap. Razumab use in India has already gone multifold in last 2 years after resolution of safety issues. Razumab is available at 30% discount compared to reference biologic ranibizumab in India and is the only similar biologic to ranibizumab being used clinically. Aflibercept has gained the market share in Europe and the US significantly in recent past. However, there are no significant financial data available from lower income countries. Cost-effective biosimilar to aflibercept might shift the momentum.
How would innovator companies protect their market share?
Innovator companies have realized that entry of biosimilars could significantly impact their sales and margins; hence, they are gearing up for the competition with strategies such as sustained drug delivery device for ranibizumab which can be a game changer for them. 27 Apart from the development of newer scientific strategies, they have an option of patent extensions such as in case of aflibercept, which might extend its claims up to June 2023 rather than 2021. They can also file patent infringement suits. From the marketing perspective, they can highlight small price difference from innovator molecules and can also try to create some doubts in physicians and patients mind about the branded and biosimilar.
Conclusion
Ophthalmology, especially retinal disease management, might see a big change in the coming few years as more 
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Sharma et al and more biosimilars are approved for the clinical use in both developing and developed world. It remains to be seen how well the drugs will be priced and how the innovator companies will protect their market share.
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